This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Europe

£200 Savings Ends In:

  • 00
  • 00
  • 00
  • 00
4 - 6 June, 2024
Excel London Platinum Suite

Andrew Buchanan, Ph.D.
Principal Scientist, Biologics Engineering at AstraZeneca


Andrew Buchanan is an experienced discovery scientist, contributing to 18 antibody-based drugs entering first-time in human clinical studies of which to date three are marketed products. He is a versatile critical thinker with 22 years of experience (Cambridge Antibody Technology, MedImmune and AstraZeneca), and has lead teams responsible for platform technologies and drug pipeline delivery to first in human studies. His current focus is on AI/ML for biologics, tissue targeting technologies and biologics science innovation. He was elected Fellow of the Royal Society of Chemistry in 2020 and with colleagues, postdocs, and PhD students, contributed to over 35 original manuscripts and patents.

Agenda Sessions

  • The Challenges of Developing and Translating Agonist Therapeutics